TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of UGSB and GA to IV Narcotics and GA for Post-Op Pain in Children With Supracondylar Fractures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1) Supracondylar fracture (2) Age 2-17 years (3) American Society of Anesthesiologists Status 1 -3 (4) Scheduled for closed reduction with percutaneous pinning under general anesthesia~Exclusion Criteria:~1. Pulseless extremity~2. Compromised neurologic status on exam (specifically assessment of radial, ulnar, and median nerve)~3. Known allergy to local anesthetics (7) Not scheduled for closed reduction with percutaneous pinning under general anesthesia~4. Bleeding diathesis~5. American Society of Anesthesiologist (ASA) status 4 or higher.~6. Sleep apnea by polysomnography

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound Guided Supraclavicular block (Type: ACTIVE_COMPARATOR): Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
- IV Opioids (Type: ACTIVE_COMPARATOR): Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female; 18-75 years old~* Diagnosis of Crohn's disease for at least 3 months prior to screening~* Confirmation of Crohn's disease by endoscopic or imaging examination~* Moderately active Crohn's disease at baseline, defined as:~* CDAI ≥220 and ≤450~* Active disease despite prior treatment with corticosteroids for at least 2 weeks, or immunosuppressants for at least 3 months. Treatment with azathioprine, 6-MP or MTX is allowed but must have been on a stable dose for at least 10 weeks, corticosteroids are allowed but must have been on a stable doses of prednisolone not exceeding 40 mg for two weeks prior to baseline. Immunosuppressants other than those listed above, such as cyclosporine, tacrolimus and mycophenolate, are not allowed and must be stopped (wash-out periods defined in the protocol);~Exclusion Criteria:~* Body Mass Index \>34~* Positive PPD tuberculin skin test or QuantiFeron test~* Any subject with evidence of active pulmonary disease or evidence of latent tuberculosis or fungal infection at screening or within past 3 months~* Symptoms associated with active bowel structuring disease and pre-stenotic dilation on radiographs~* Fistulizing disease if complicated by sepsis and/or untreated abscess~* Multiple bowel surgeries and clinically important short bowel syndrome defined as an inability to maintain caloric intake~* Use of certain medications as specified in the protocol~* Clinical improvement due to other Crohn's therapy~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AIN457 (Type: EXPERIMENTAL): AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to AIN457 was given as an infusion at day 1 and day 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years~* Fever, respiratory symptoms and constitutional symptoms compatible with influenza infection~* Influenza A or B infection in the local community~* Onset of illness no more than 48 hours before presentation~* Willing and able to provide comply with protocol requirements~Exclusion Criteria:~* Severity of illness requiring or anticipated to require in-hospital care~* High risk of complications from influenza per IDSA (Infectious Diseases Society of America) guidelines or current CDC (Centers for Disease Control) criteria~* Females pregnant, breast-feeding or sexually active without birth control~* Vaccination for seasonal influenza or H1N1 on or after August 1, 2009~* Treatment with antiviral medication for influenza within 1 month prior to screening~* Treatment with nitazoxanide or any investigational drug within 1 month prior to screening~* Known sensitivity to nitazoxanide or any excipients~* Unable to take oral medications~* Chronic kidney or liver disease or known impaired hepatic and/or renal function~* Other pre-existing chronic infection undergoing or requiring medical therapy~* Pre-existing illness placing subject at unreasonably increased risk by participation in study~* Unlikely to comply with the requirements of this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of QRH-882260 Heptapeptide Application in the Colon

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject meets at least one of the following criteria:~* At increased risk for colorectal cancer (CRC) and colonic polyps~* Known colonic adenomas scheduled for colonic resection~* Scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia~* Subject is scheduled for outpatient colonoscopy in the Medical Procedures Unit at UMHS~* Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) Standard practice guidelines for safely proceeding with the procedure will be sufficient for the study~* Age 18 to 100 years~* Willing and able to sign informed consent~Exclusion Criteria:~Subjects with known allergy or negative reaction to Cy5 (a near-infrared fluorophore) or derivatives~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Topical QRH Heptapeptide Administration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Diagnosis of diffuse large B-cell lymphoma, CD20-positive, according to the World Health Organization Classification, stages II-IV or limited stage I disease that is bulky (more than 10 cm) or with International Prognostic Index (IPI) score \> 1.~* 2. Patients must not have had prior chemotherapy, radiotherapy or immunotherapy. A short course (\< 2 weeks) of corticosteroids is allowed.~* 3. Adequate paraffin-embedded tumor specimen must be available for gene expression analysis and immunohistochemistry prior to initiation of therapy. (If the specimen is deemed inadequate, the subject can be retroactively screen failed, as this does not change the treatment regimen).~* 4. Baseline measurements and evaluation must be obtained within 4 weeks before first treatment.~* 5. Age \>18 years.~* 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-3.~* 7. Adequate organ function:~  * White Blood Cells count (WBC) \>2500/µL~ * Absolute Neutrophil Count (ANC) \> 1000/µL (unless due to disease in marrow)~ * platelet count \>100,000/µL (unless due to disease in marrow)~ * creatinine \< 2.0 mg/dL,~ * bilirubin \< 1.5 mg/dL (may be 1.5-3.0 mg/dl if due to liver involvement by lymphoma)~ * Serum Glutamic Oxaloacetic Transaminase (SGOT)/ Serum Glutamic Pyruvic Transaminase (SGPT) \<3 x upper limit of normal.~* 8. Female patients must not be pregnant or breast feeding.~* 9. Women of childbearing potential and men must be strongly advised to use an accepted and effective method of contraception.~* 10. Patients must have left ventricular ejection fraction of \>45%.~* 11. Provision of written informed consent.~Exclusion Criteria:~* 1. Patients with a second malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix unless the tumor was treated with curative intent at least two years previously; and; the patient continue to be free of evidence of recurrence.~* 2. Patients with HIV infection as these patients are managed on dedicated protocols.~* 3. Patients with active central nervous system (CNS) lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- R-CHOP (Type: EXPERIMENTAL): Patients will receive R-CHOP for 6 to 8 cycles:~* Rituximab 375 mg/m2 on day 1~* Cyclophosphamide 750 mg/m2 IV on day 1~* Doxorubicin 50 mg/m2 on day 1~* Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1~* Prednisone 100 mg orally days 1-5, repeated every 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18 years or older~* Confirmed and measurable metastatic melanoma with at least one measurable lesion for evaluation of response~* Meets the requirements for HD IL-2 therapy per Institutional guidelines~* Meets the requirements for ipilimumab therapy per Institutional guidelines~* Treatment naïve or has received only one systemic therapy apart from adjuvant therapy.~* At least 4 weeks since last adjuvant therapy or other cancer treatment~* Willing and able to give informed consent and participate in study procedures as described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will also be asked to participate in the 10PLK13 PROCLAIM registry study.~Exclusion Criteria:~* Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis~* Pregnant, nursing or planning to become pregnant~* Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI at least 6 weeks after definitive therapy are acceptable.)~* Received prior ipilimumab therapy (Prior Adjuvant Ipilimumab and Adjuvant Interferon are permitted with a minimum 4 week washout)~* Received prior HD IL-2 therapy.~* Received investigational drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical studies, including the 10PLK13 PROCLAIM registry study.~* Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm 1 (Type: ACTIVE_COMPARATOR): Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
- Treatment Arm 2 (Type: ACTIVE_COMPARATOR): Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with PD within a maximum of 3 years prior to screening.~* Has not received levodopa or any other treatment for PD, herein referred to as symptomatic PD medication (including but, not limited to, dopamine agonists, amantadine, anticholinergics, monoamine oxidase type B (MAO-B) inhibitors, or safinamide) for at least 12 weeks prior to Day 1. Maximum total duration of prior PD regimens should not exceed 30 days.~* Score of less than equal to (\<=) 2.5 on the Modified Hoehn and Yahr Scale.~* Screening dopamine transporter (DaT)/ single-photon emission computed tomography (SPECT) results consistent with neurodegenerative Parkinsonism (central reader).~Key Exclusion Criteria:~* Presence of freezing of gait.~* History of or positive test result at Screening for human immunodeficiency virus (HIV) or hepatitis C virus antibody (anti-HCV).~* Screening value for hemoglobin less than (\<)12 gram per deciliter (g/dL) for men or \<11 g/dL for women.~* Montreal Cognitive Assessment (MoCA) score \<23 or other significant cognitive impairment or clinical dementia.~* History of any brain surgery for PD.~* Participation in any passive or active immunotherapy targeting alpha-synuclein or other PD-related protein.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: BIIB054 Dose A (Type: EXPERIMENTAL): Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
- Cohort 2: BIIB054 Dose B (Type: EXPERIMENTAL): Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
- Cohort 3: BIIB054 Dose C (Type: EXPERIMENTAL): Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
- Cohorts 1-3: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients without evidence of any clinically apparent arrhythmia recurrence during at least six months after last catheter ablation of AF.~* Willing and able to provide informed consent~Exclusion Criteria:~* Patients who do not meet all of the above listed inclusion criteria.~* Patients with significant valvular heart disease or mechanical valve.~* Patients with hypertrophic cardiomyopathy.~* Patients with chronic renal impairment with creatinine clearance rate of \< 30 mg/dl.~* Patients with contraindication to long-term OAC.~* Patients who had a stroke within one year prior to enrolment.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antiplatelet therapy (Type: EXPERIMENTAL): acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
- Low-dose OAC therapy (Type: EXPERIMENTAL): Edoxaban of 30mg (Reduced dose of 15mg if body weight \< 60kg, CCr\< 50 ml/min, concomittant use of P-gp)
- Standard-dose OAC therapy (Type: ACTIVE_COMPARATOR): Edoxaban of 60mg (Reduced dose of 30mg if body weight \< 60kg, CCr\< 50 ml/min, concomittant use of P-gp)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have been enrolled in the two year follow-up phase of ATTRACT and have continued treatment with the site investigator~* Signature of informed consent.~Exclusion Criteria:~* Not specified in the protocol.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): Subjects previously enrolled in the ATTRACT trial from three Canadian sites.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Body Composition Optimization Intervention RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adults, at or above 18 years of age~* BMI over 40kg/m2~* Presenting to arthroplasty-obesity clinic with desire for a total joint arthroplasty procedure~Exclusion criteria:~* Has a pacemaker or other electronic pacemaker placement~* Inability to stand unsupported for 60-90 seconds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Normal Care
- Nutritional consultation (Type: EXPERIMENTAL): Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, at least 18 years of age~2. Histologically confirmed non-small cell lung cancer with at least one site of disease \> 1 cm by at least one type of standard imaging (e.g. CT, chest x-ray, MRI)~3. Recommended to start systemic therapy which includes pemetrexed and a platinum-based agent.~4. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.~5. Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician.~Exclusion Criteria:~1. Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test at the time of the screening visit.~2. Patients with only a single site of primary lung cancer who have undergone or are recommended to undergo radiation therapy to that site will not be eligible, the inclusion of patients who may be undergoing radiation therapy to ancillary disease sites may be allowed to enter the study at the discretion of the PI if it is not felt to affect the ability to capture FLT information for at least one primary site of disease.~3. Patients who have received chemotherapy within 2 weeks of enrollment will be excluded from the study.~4. Patients who have undergone cancer surgery removing a significant portion of active disease, in the opinion of an investigator, within 2 months prior to study enrollment will be excluded.~5. Inability to tolerate imaging procedures in the opinion of the investigator or treating physician~6. Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.~7. Unwilling or unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients will be enrolled in a single arm of the study (Type: EXPERIMENTAL): All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues